Charles River Laboratories International, Inc. $CRL Shares Sold by Macquarie Group Ltd.

Macquarie Group Ltd. lowered its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 12.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 202,141 shares of the medical research company’s stock after selling 27,950 shares during the quarter. Macquarie Group Ltd.’s holdings in Charles River Laboratories International were worth $40,323,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Charles River Laboratories International by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock worth $1,174,374,000 after acquiring an additional 47,432 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Charles River Laboratories International by 27.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,442,224 shares of the medical research company’s stock valued at $287,703,000 after purchasing an additional 311,319 shares in the last quarter. Geode Capital Management LLC grew its holdings in Charles River Laboratories International by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company’s stock worth $254,186,000 after acquiring an additional 9,756 shares in the last quarter. Invesco Ltd. grew its holdings in Charles River Laboratories International by 1.0% during the 3rd quarter. Invesco Ltd. now owns 1,249,178 shares of the medical research company’s stock worth $195,446,000 after acquiring an additional 12,035 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in Charles River Laboratories International by 13.4% during the 3rd quarter. Bank of America Corp DE now owns 1,163,348 shares of the medical research company’s stock worth $182,017,000 after acquiring an additional 137,335 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on CRL shares. Wall Street Zen lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Robert W. Baird set a $213.00 price objective on shares of Charles River Laboratories International in a report on Friday, May 8th. Barclays raised their price objective on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. CLSA raised shares of Charles River Laboratories International from a “hold” rating to an “outperform” rating and raised their price objective for the stock from $167.00 to $219.00 in a report on Friday, May 29th. Finally, Mizuho set a $192.00 price target on shares of Charles River Laboratories International in a research report on Friday, May 8th. Eleven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $208.50.

Charles River Laboratories International Trading Down 0.4%

Charles River Laboratories International stock opened at $187.39 on Friday. The firm’s 50-day moving average is $173.50 and its 200-day moving average is $182.41. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. Charles River Laboratories International, Inc. has a 1 year low of $143.06 and a 1 year high of $228.88. The company has a market cap of $9.03 billion, a P/E ratio of -49.84, a PEG ratio of 2.15 and a beta of 1.46.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. During the same period last year, the firm posted $2.34 EPS. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, equities analysts expect that Charles River Laboratories International, Inc. will post 11.04 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.